Literature & Media

What’s new with benzodiazepine NPS: Here come the ethyl analogues!

Webinars

Benzodiazepines were discovered in the 1950s and were rapidly adopted as prescription medicines for the treatment of a variety of conditions, such as anxiety or use as sedatives. However, the increase in popularity of benzodiazepines, along with their addictive properties, also led to an increase in the misuse and abuse of these compounds. 

In this presentation, Kirk Hering, Director of Process Exploration and Psychoactive Substance Chemistry at Cayman Chemical, reviews the known metabolic pathways of established designer benzodiazepines and discusses the metabolites likely to form from emerging NPS ethyltriazolobenzodiazepines.

Presented as part of the CFSRE's 2026 Current Trends in Forensic Toxicology Symposium. 

Do you have a question or comment for the presenter? Let us know. 


Cayman ChemicalCayman ChemicalCayman Chemical

Receive Our News & Literature Directly to Your Inbox!

Log in or register to subscribe to our email list. You will receive emails packed with new products and content that match your research interests. We only email once a week and you can unsubscribe at any time.